SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.
The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.
SenesTech, Inc. (SNES) reporting: Lynn Yako filed an Initial Statement of Beneficial Ownership (Form 3) identifying her relationship to the issuer as a Director and reporting no securities beneficially owned. The event date listed is 07/05/2025 and the form bears a signature dated 08/02/2025. The filing includes an exhibit: a Limited Power of Attorney.
SenesTech, Inc. (a Delaware corporation with principal place in Surprise, Arizona) filed a Form D disclosing a Regulation D private offering of common stock warrants that raised an aggregate of $273,539. The filing reports the total amount sold as $273,539 with $0 remaining to be sold and indicates the offering relied on Rule 506(b). Five investors participated and the issuer states $0 of the gross proceeds were used to pay named executive officers.
The placement agent disclosed is H.C. Wainwright & Co., LLC, and the filing estimates sales commissions of $474,589. It also discloses placement agent warrants to purchase up to 72,944 shares at an exercise price of $5.4219 per share, plus accountable expenses and a management fee. The offering is not tied to a business combination and is not intended to last more than one year.
PFS Cap Mgt Co and PFS Trust report beneficial ownership of 340,000 shares of SenesTech, Inc., representing 9.99% of the outstanding common stock based on 2,247,691 shares outstanding as of June 24, 2025, per the company's Prospectus Supplement No. 2. The reported position includes 120,000 shares issuable upon exercise of warrants held by the Trust but those warrants are subject to a 9.99% exercise blocker, so the Reporting Persons cannot currently exercise all warrants to exceed the 9.99% threshold. The filing shows shared voting and dispositive power over 340,000 shares and no sole voting or dispositive power. The Schedule 13G/A is signed by John David Kessler on August 12, 2025.